An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main purpose of this study is to determine if applying mupirocin into soldiers noses who are colonized with methicillin-resistant Staphylococcus aureus (MRSA) will reduce infections in them and their cohort of fellow soldiers.
| Condition | Intervention |
|---|---|
|
Community-Acquired MRSA Infections Abscesses Cellulitis Folliculitis |
Drug: Mupirocin (drug) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Prevention |
| Official Title: | An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus Infection in Soldiers: a Controlled Trial |
- Soft tissue infections in subjects who received the study medication and soft tissue infections in the study cohorts.
- Changes in S. aureus carriage rates (including MRSA).
| Estimated Enrollment: | 3000 |
| Study Start Date: | January 2005 |
| Estimated Study Completion Date: | December 2005 |
Community-acquired MRSA infections are increasingly common in the community and in particular among certain groups of which soldiers are one. Many researchers and clinicians have postulated that one method to prevent infections is to selectively eradicate CA-MRSA in those who are colonized with the pathogen. The two main purposes of the study are: to determine if selective CA-MRSA eradication in subjects reduces infections in the CA-MRSA colonized individual; and to determine if selective CA-MRSA eradication in subjects reduces infections in the study cohort. Other information concerning CA-MRSA includes: prevalence, risk factors, and virulence data. The population will be soldiers enrolled in the combat medic training class at Ft. Sam Houston. We will enroll approximately 3000 soldiers over a two year period. After informed written consent, we will culture their anterior nares nares and administer questionnaires at the beginning and at the end of the study, following them prospectively for infections. The follow-up period will be 16 weeks. For those with CA-MRSA in their nares, they will be randomized (by cohort) to receive either 5 days of mupirocin or placebo.
Eligibility| Ages Eligible for Study: | 17 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:Soldiers enrolled into the combat medic course at Ft. Sam Houston, TX.
-
Exclusion Criteria: Allergy to mupirocin.
-
Contacts and Locations| United States, Texas | |
| Brooke Army Medical Center | |
| Ft. Sam Houston, Texas, United States, 78234 | |
| Principal Investigator: | Michael W Ellis, MD | Brooke Army Medical Center |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00289588 History of Changes |
| Other Study ID Numbers: | C.2004.163 |
| Study First Received: | February 9, 2006 |
| Last Updated: | February 13, 2006 |
| Health Authority: | United States: Federal Government |
Keywords provided by Brooke Army Medical Center:
|
Methicillin-resistant Staphylococcus aureus Staphylococcus aureus MRSA CA-MRSA |
Additional relevant MeSH terms:
|
Abscess Cellulitis Folliculitis Staphylococcal Infections Suppuration Infection Inflammation Pathologic Processes Skin Diseases, Infectious Connective Tissue Diseases Hair Diseases Skin Diseases |
Gram-Positive Bacterial Infections Bacterial Infections Methicillin Mupirocin Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on June 18, 2013